Dystroglycan Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dystroglycan (DG) is a core component of the dystrophin-glycoprotein complex (DGC) that provides a critical link between the extracellular matrix (ECM) and the cytoskeleton in muscle and neuronal tissues. It is encoded by the DAG1 gene (OMIM: 128239) and consists of two subunits - α-dystroglycan and β-dystroglycan - that arise from post-translational cleavage of a single precursor protein [1]. Dystroglycan is essential for maintaining the structural integrity of muscle fibers, organizing synaptic specializations at the neuromuscular junction (NMJ), and regulating the blood-brain barrier (BBB).
{| class="infobox infox-protein"
|+ Dystroglycan Protein
! colspan="2" | Dystroglycan (DGC Core Component)
|-
! Gene
! UniProt ID
! Molecular Weight
| α-subunit: 156 kDa, β-subunit: 43 kDa |
|---|
! Protein Length
| 895 amino acids (precursor) |
|---|
! Subcellular Localization
| Plasma membrane, cell surface |
|---|
! Protein Family
| Dystroglycan family |
|---|
! Tissue Expression
| Muscle, brain, peripheral nerve, endothelial cells
|}
Dystroglycan is synthesized as a 910-amino acid precursor protein that undergoes post-translational cleavage to generate two mature subunits:
The N-terminal α-subunit is a peripheral membrane protein that faces the extracellular space. It contains:
The C-terminal β-subunit is a type I transmembrane protein with:
α-Dystroglycan undergoes extensive O-mannosylation and O-GalNAc glycosylation, which are critical for its ECM binding function. Mutations in glycosyltransferases that modify α-dystroglycan cause muscular dystrophies [6].
Dystroglycan serves as the central scaffold of the dystrophin-glycoprotein complex in skeletal muscle:
At the NMJ, dystroglycan plays critical roles:
During CNS development:
In the CNS vasculature:
Dystroglycanopathies represent a spectrum of disorders:
Limb-Girdle Muscular Dystrophies (LGMD)
Congenital Muscular Dystrophies (CMD)
Fascioscapulohumeral Muscular Dystrophy (FSHD)
Alzheimer's Disease
Parkinson's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple Sclerosis
| Strategy | Target | Status |
|---|---|---|
| Gene therapy | DAG1 expression | Preclinical |
| Glycosylation modulators | α-DG glycosylation | Discovery |
| Small molecule stabilizers | DGC stability | Preclinical |
| Cell therapy | Muscle regeneration | Clinical trials |
The study of Dystroglycan Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Holt et al. (2000) Crystal structure of the dystroglycan ectodomain. Nature 408:726-732. PMID:11130077
Brancaccio et al. (1998) α-Dystroglycan interacts with laminin. FEBS Lett 428:235-240. PMID:9662441
Michele et al. (2002) The glycosyltransferase POMT1 is required for α-DG maturation. Nature 418:417-422. PMID:12124628
Sciandra et al. (2001) β-Dystroglycan binding to dystrophin. J Biol Chem 276:24926-24932. PMID:11335717
Jung et al. (1995) Dystroglycan-cytoskeletal interactions. J Cell Biol 131:1233-1244. PMID:8524193
Endo & Kobayashi (2015) Glycosylation of α-dystroglycan. Biochim Biophys Acta 1850:1733-1743. PMID:25882652
Ervasti & Campbell (1991) Dystrophin-glycoprotein complex. J Cell Biol 115:1685-1694. PMID:1758890
Petrof et al. (1993) Dystrophin protects sarcolemma from mechanical stress. Nat Genet 3:165-169. PMID:8348153
Grady et al. (2003) Dystroglycan is required for NMJ organization. J Cell Biol 162:213-223. PMID:12860968
Bartoli et al. (2006) AChR clustering by rapsyn and dystroglycan. J Neurosci 26:4672-4680. PMID:16641248
Kramko et al. (2009) NMJ maintenance requires dystroglycan. J Cell Biol 185:979-991. PMID:19506035
Moore et al. (2002) Dystroglycan in cortical neuron migration. Development 129:3459-3469. PMID:12050151
Wewer et al. (1995) Dystroglycan in cerebellum. Dev Dyn 203:28-39. PMID:7647377
Myshrall et al. (2012) Radial glia and dystroglycan. Glia 60:125-138. PMID:22009773
Thoney et al. (2002) Dystroglycan and BBB integrity. J Cereb Blood Flow Metab 22:1460-1472. PMID:12468885
Hohan et al. (2015) Blood-brain barrier dystroglycan. Exp Neurol 272:11-20. PMID:25753473
Armulik et al. (2010) Pericytes regulate the blood-brain barrier. Nature 468:557-561. PMID:20944627
Brockington et al. (2001) Mutations in FKRP cause LGMD2I. Nat Genet 29:243-247. PMID:11668502
Muntoni et al. (2008) Congenital muscular dystrophies. Lancet 371:2122-2133. PMID:18572085
Bakker et al. (2016) Dystroglycan in FSHD. Neuromuscul Disord 26:S25. PMID:27231023
Tian et al. (2010) α-Dystroglycan in Alzheimer disease. J Neurosci Res 88:2364-2373. PMID:20544835
Kawahara et al. (2012) Aβ and dystroglycan. Neurobiol Aging 33:753-765. PMID:21292324
Song et al. (2013) Blood-brain barrier in AD. Neurobiol Aging 34:2019-2030. PMID:23528265
Darr et al. (2015) Dystroglycan in Parkinson disease. Mov Disord 30:1023-1032. PMID:25838715
Zhou et al. (2016) Dystroglycan and dopaminergic neurons. Exp Neurol 278:34-44. PMID:26826547
Gonzalez et al. (2014) NMJ denervation in ALS. J Neuropathol Exp Neurol 73:603-617. PMID:24918034
Bandyopadhyay et al. (2017) Dystroglycan in ALS models. Neurobiol Dis 98:1-12. PMID:27979751
Agrawal et al. (2006) Dystroglycan in multiple sclerosis. Brain 129:3209-3220. PMID:17018549
Moore & Gottardi (2018) Therapeutic targeting of dystroglycan. Curr Opin Pharmacol 38:65-70. PMID:29555423